Key result
Sirolimus-eluting stents did not reduce 12-month major adverse cardiac events compared to paclitaxel-eluting stents in patients with acute STEMI.
Why the study?
Does sirolimus-eluting stent deployment reduce major adverse cardiac events compared to paclitaxel-eluting stent deployment in acute STEMI patients undergoing primary angioplasty?
RCT (n=308)
randomly assigned
Does sirolimus-eluting stent deployment reduce major adverse cardiac events compared to paclitaxel-eluting stent deployment in acute STEMI patients undergoing primary angioplasty?
In patients with acute STEMI undergoing primary angioplasty, sirolimus-eluting stents significantly reduced angiographic restenosis and late loss compared to paclitaxel-eluting stents, though the reduction in 12-month MACE was not statistically significant.
Answers are grounded in this paper and cite their sources.
Sirolimus-eluting stents showed no MACE superiority versus paclitaxel-eluting stents in STEMI; leaves open whether angiographic gains improve clinical outcomes.
OBJECTIVE: The aim of this study was to compare effectiveness of the Sirolimus- (SES) and Paclitaxel-eluting stent (PES) in primary angioplasty for acute ST-elevation myocardial infarction (STEMI). BACKGROUND: It has been reported that SES and PES have been more effective than bare-metal stents in reducing restenosis and cardiac events in a broad range of patients with coronary artery disease. However, it is unknown whether there may be differences between these two drug-eluting stents in terms of efficacy in the setting of acute STEMI. METHODS: Acute STEMI patients (n = 308) undergoing primary angioplasty were randomly assigned to SES (n = 154) or PES (n = 154) deployment. The routine angiographic follow-up was performed at 6 months and clinical follow-up data was obtained at 12 months. The primary end point was major adverse cardiac events (MACE) including death, reinfarction, stent thrombosis, and target lesion revascularization (TLR) at 12 months. RESULTS: The baseline clinical, angiographic, and procedural characteristics were similar between the 2 groups. Two patients (all from the PES group) experienced stent thrombosis (1 acute and 1 subacute). The SES group revealed lower in-segment restenosis (5.9% vs. 14.8%, P = 0.03) and in-segment late loss (0.09 +/- 0.45 vs. 0.33 +/- 0.68 mm, P = 0.002) than PES group on follow-up angiography. Twelve-month TLR rates (2.6% vs. 6.5%, P = 0.17) were similar between two groups. MACE rates were lower in the SES group than in the PES group, but it did not reach statistical significance (5.8% vs. 11.7%, P = 0.07). CONCLUSION: In the setting of primary angioplasty for STEMI, there were no statistically significant differences between the SES and the PES in terms of 12-month MACE. However, binary angiographic in-segment restenosis and in-segment late loss were significantly lower in the SES group.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2008) conducted an RCT in acute ST-elevation myocardial infarction (STEMI) (n=308). Sirolimus-eluting stent (SES) vs. Paclitaxel-eluting stent (PES) was evaluated on major adverse cardiac events (MACE) including death, reinfarction, stent thrombosis, and target lesion revascularization (TLR) at 12 months (p=0.07). Sirolimus-eluting stents did not reduce 12-month major adverse cardiac events compared to paclitaxel-eluting stents in patients with acute STEMI.
Synapse has enriched 10 related papers. Consider them for comparative context: